Atezolizumab, a humanized monoclonal antibody of isotype IgG1, [11,54,55] was the first PD-1/PD-L1 checkpoint inhibitor approved by the FDA and accepted by the European Association of Urology (EUA) [10] as second-line therapy for patients with advanced BC [56]. The gene discussed is CD274; the disease is breast cancer.